SYNTHESIS OF 1,3-DISUBSTITUTED HEXAHYDROPYRIMIDINE DERIVATIVES FROM DIBENZOYL METHANE, ACETYLACETONE, ETHYL ACETOACETATE: ONE-POT FeCl₃-CATALYZED MANNICH REACTION

Abdullah Saleh, Martha Morton, and John D’Angelo

1Department of Chemistry, Hashemite University, Zarqa, Jordan
2Department of Chemistry, University of Nebraska, Lincoln, Nebraska, USA
3Division of Chemistry, Alfred University, Alfred, New York, USA

Graphical Abstract

Abstract

1,3-Disubstituted hexahydropyrimidin-5-yl(phenyl)methanone (products 1-5) were prepared from the reaction of dibenzoylmethane with primary amines and formaldehyde in the presence of Lewis acid catalyst at ambient temperature. Replication of the
reaction with acetylacetone and ethyl aetoacetate yielded 1,1′-(1,3-disubstituted hexahydropyrimidine-5,5-diyl)diethanone (products 6–10) and ethyl 5-acetylhexahydropyrimidine-5-carboxylate (products 11–13), respectively. Yields obtained ranged from 69 to 89%.

Keywords Debenzoylation; hexahydropyrimidines; Mannich reaction

INTRODUCTION

Hexahydropyrimidines are compounds with broad biological activities and have been found in many natural products.[1–5] A number of these compounds are suspected to have important biological activities.[6–16] Recent in vitro testing of some hexahydropyrimidine derivatives showed promising new leads with pharmaceutical interest. Biological activities include, for example, leishmanicidal,[17] antimicrobial,[7] and cytotoxic activities.[18] Several hexahydropyrimidine derivatives also have been evaluated for their anti-HIV-1 activity.[19,20] Anti-inflammatory and analgesic activities of some hexahydropyrimidines were evaluated with comparable results to diclofenac sodium gel (Relaxyl gel) and aspirin.[21,22] Additionally, hexahydropyrimidines were important as transport molecules for tumor inhibition and antineoplastic

Scheme 1. Synthesis of hexahydropyrimidines using dibenzoylmethane, primary amine, and formaldehyde.
Table 1. Yields and structures of products obtained according to Scheme 1

| Parameter | Entry | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 |
|-----------|-------|----|----|----|----|----|----|----|----|----|----|----|----|----|
| R₁        |       | Ph | Ph | Ph | Ph | Ph | Me | Me | Me | Me | Me | Me | Me | Me |
| R₂        |       | —  | —  | —  | —  | —  | Me | Me | Me | Me | Me | Me | OEt| OEt|
| R₃        |       | p-Cl-Ph | cyclohexyl | p-Br-Ph | n-Hexyl | p-OMe-Ph | p-Cl-Ph | Cyclohexyl | p-Br-Ph | p-OMe-Ph | p-Cl-Ph | Cyclohexyl | p-Br-Ph |
| Yield (%) |       | 77 | 71 | 89 | 69 | 86 | 86 | 85 | 83 | 87 | 89 | 81 | 84 | 85 |
Acid-mediated aminomethylation with formaldehyde and primary amines at the \( \alpha \)-position of 1,3-dicarbonyl compounds is a well-established procedure for the synthesis of hexahydropyrimidines.\(^{29-34}\) Indeed several 1,3-dicarbonyl compounds have been reported to undergo this reaction under mild conditions at room temperature in the presence of catalytic amounts of FeCl\(_3\).\(^{35}\) However, reports of this reaction with dibenzoylmethane (DBM) are lacking. In an effort to prepare hexahydropyrimidine derivatives of DBM, the known one-pot procedure for related systems using FeCl\(_3\) was initially pursued.\(^{35}\) Unexpectedly, when the products were isolated and identified, the monocarbonyl derivatives were obtained (Scheme 1, 1–5). The expected dicarbonyl derivatives were not detected. It was evident that one of the benzoic acid, a logical by-product of the debenzoylation, was confirmed by NMR, further supporting that conclusion. When DBM was replaced by either acetylacetone (ACAC) or ethyl acetoacetate (EAA), the expected dicarbonyl products were successfully isolated and characterized (Scheme 1, Table 1), suggesting that this observation is unique to the dibenzoyl system.

**RESULTS AND DISCUSSION**

Primary amine (Table 1) was reacted with DBM in the presence of aqueous formaldehyde and a catalytic amount of FeCl\(_3\) (5 mol\%) in dichloromethane at room temperature (Scheme 1). The reaction was monitored by thin-layer chromatography (TLC). The product obtained was thoroughly purified and characterized by standard spectroscopic and analytical methods to show that one of the benzoic acid, a logical by-product of the debenzoylation, was confirmed by NMR, further supporting that conclusion. When DBM was replaced by either acetylacetone (ACAC) or ethyl acetoacetate (EAA), the expected dicarbonyl products were successfully isolated and characterized (Scheme 1, Table 1), suggesting that this observation is unique to the dibenzoyl system.

The reaction of ACAC, according to Scheme 1, was repeated at elevated temperature (refluxing temperature of chloroform). It was found that higher temperature did not affect the outcome of this reaction. In conclusion, all of the evidence, taken together, makes it apparent that the observed carbonyl group fission can be associated to the DBM system.

It turns out that the observed carbonyl group cleavage is not entirely unusual. There are several literature precedents in which deacylation and debenzoylation have been observed for 1,3-dicarbonyl compounds.\(^{37,38}\) An interesting debenzoylation have been observed for \( \alpha,\alpha \)-dialkylated dibenzoylmethane derivative when treated with alkali.\(^{39}\) However, the mechanism is still largely speculative.

The generally accepted mechanism for the reaction shown in Scheme 1 has been recently discussed by Mukhopadhyay et al.\(^{35}\) With this mechanism in mind, currently it is not clear at which step the benzoic acid is lost. In an effort to
determine when the debenzylation was occurring, DBM was mixed with FeCl₃ alone under the reaction conditions. When the product mixture was analyzed by TLC, the formation of acetophenone, a putative by-product of the debenzylation should DBM denbobylate in this case, was not detected. Similarly, benzoic acid did not form either. It is highly likely that both water (from the aqueous formaldehyde) and the Lewis acid catalyst, FeCl₃, are playing a role. The formation of stoichiometric quantities of benzoic acid equivalent to that of the main product suggests that water is essential. The presence of Lewis acid catalyst ought to facilitate the nucleophilic addition of water to the carbonyl group. However, why this appears to only occur in the DBM case remains unclear. Additionally, the Lewis acid iron(III) chloride catalyst form is not known at this stage. A hydrated form (FeCl₃·6H₂O) of the catalyst in the presence of water cannot be ruled out.

It is possible that the electron-withdrawing nature of the benzene ring just sufficiently activate the carbonyl carbon. If this were the case, systems with an electron-donating group attached to the benzene ring, or a mixed system containing only one benzoyl group may result in different reactions. Unfortunately, the former, to our knowledge, is not commercially available.

The observed debezoylation with DBM-hexahydropyrimidines is probably due to the FeCl₃-assisted water nucleophilic addition to one of the carbonyl carbons of the initial hexahydropyrimidine product (Scheme 2). A transient intermediate I will be a logical product of this addition. The adjacent phenyl group will also play an assistive role in this nucleophilic addition. When DBM is compared to EAA and ACAC, the absence of this additional assistance might explain the survival of the dicarbonyl hexahydropyrimidine products of EAA and ACAC. Subsequently, the decomposition of intermediate I will ultimately lead to the observed cleavage of the carbon–carbon bond. The isolation of benzoic acid by-product supports that conclusion.

Literature procedures of DBM hexahydropyrimidine synthesis[36] require heating at much greater temperatures and less commercially available starting materials. The present methodology has the advantages of taking place at room temperature using simpler starting material and with comparable yields although with lower overall atom economy.

**EXPERIMENTAL**

Column chromatography was performed on 230- to 400-mesh silica gel (Merck) and TLC plates with silica gel 60 F₂₅₄ (Merck) were used. A mixture of
AcOEt/hexane (30%) was used as eluent for all chromatographic separations. Infrared (IR) spectra were recorded as either thin films or KBr discs on Magna-IR 560 Nicolet FT-IR spectrometer and are reported in wave numbers (cm⁻¹). NMR spectra were recorded at room temperature on Brucker-Avance (III) spectrometer at 400 MHz using CDCl₃ as solvent. Chemical shifts are expressed in δ values (ppm) relative to tetramethylsilane (TMS) as internal standard for ¹H and relative to TMS (0.00 ppm) or to CDCl₃ (77.05 ppm) for ¹³C NMR spectra. Coupling constants J values are reported in hertz (Hz). Elemental analyses were performed on a EuroEA 3000, EuroVector CHN analyzer. Structural assignments of the derived compounds were established by analysis of their combined spectroscopic data.

**General Procedure**

A typical experimental procedure followed for the preparation of hexahydropyrimidines using either dibenzoyl methane, acetylacetone, or ethyl acetoacetate using FeCl₃ catalyst is as follows: A mixture of 1,3-dicarbonyl compound (1 equivalent), primary amine (2 equivalents), formaldehyde (3 equivalents, 37–41% aqueous solution), and a catalytic amount of FeCl₃ (5 mol%) was stirred for 24 h at room temperature in dichloromethane. The solvent was removed by a rotary evaporator. Crude products were purified by column chromatography with 30% ethyl acetate in hexane. Spectral and analytical data of all the compounds in Table 1 are given in the supplementary material. The spectral and analytical data of representative compounds are as follows.

**Compound 1, [1,3-Bis(4-chlorophenyl)hexahydropyrimidin-5-yl](phenyl)methanone**

White solid, FT-IR: v_max (thin film)/cm⁻¹ 3052, 2827, 1674, and 1594; ¹H NMR (400 MHz,) δ_H: 7.93 (2H, d, J = 7.4 Hz, PhH), 7.63 (1H, t, J = 7.4 Hz, PhH), 7.51 (2H, t, J = 7.4 Hz, PhH), 7.29 (4H, d, J = 8.7 Hz, ArH), 7.01 (4H, d, J = 8.7 Hz, ArH), 5.13 (1H, d, J = 11.3 Hz, N-CH-N), 4.17 (1H, d, J = 11.3 Hz, N-CH-N), 3.93–4.03 (3H, m, CH, CH), 3.34 (2H, t, J = 10.8 Hz, CH); ¹³C NMR (CDCl₃) δ_C: 199.4 (C, CO), 147.7 (C, C_aromat), 135.7 (C, C_aromat), 133.8 (CH, C_aromat), 129.4 (CH, C_aromat), 129.0 (CH, C_aromat), 128.2 (CH, C_aromat), 125.9 (C, C_aromat), 118.8 (CH, C_aromat), 68.7 (CH₂, N-CH₂-N), 52.4 (CH₂, N-CH₂), 40.6 (CH, CO-CH). Anal. calcd. for C₂₃H₂₀Cl₂N₂O: C, 67.16; H, 4.90; N, 6.81. Found: C, 67.41; H, 4.92; N, 6.79.

**Compound 6, 1,1’-[1,3-Bis(4-chlorophenyl)hexahydropyrimidine-5,5-diyl]diethanone**

White solid, FT-IR: v_max (thin film)/cm⁻¹ 3088, 2992, 1691, and 1583; ¹H NMR (400 MHz,) δ_H: 7.27 (4H, d, J = 8.8 Hz, ArH), 7.01 (4H, d, J = 8.8 Hz, ArH), 4.33 (2H, s, N-CH₂-N), 3.81 (4H, s, CH₂-N₂), 2.17 (6H, s CH₃); ¹³C NMR (CDCl₃) δ_C: 203.2 (C, CO), 147.7 (C, C_aromat), 129.3 (CH, C_aromat), 126.6 (C, C_aromat), 119.2 (CH, C_aromat), 69.2 (CH₂, N-CH₂-N), 67.1 (C, C-CO), 53.3 (CH₂, N-CH₂),
26.6 (CH₃). Anal. calcd. for C₂₀H₂₀Cl₂N₂O₂: C, 61.39; H, 5.15; N, 7.16. Found: C, 61.67; H, 5.17; N, 7.13.

**Compound 11, Ethyl 5-Acetyl-1,3-bis(4-chlorophenyl) hexahydropyrimidine-5-carboxylate**

White solid, FT-IR: \( \nu_{\text{max}} \) (thin film) cm\(^{-1}\) 3065, 2983, 1771, 1593, and 1496; \(^1^H\) NMR (400 MHz, ) \( \delta_{\text{H}} \): 7.19 (4H, d, \( J = 8.9 \) Hz, ArH), 6.94 (4H, d, \( J = 8.9 \) Hz, ArH), 4.40 (1H, d, \( J = 11.5 \) Hz, N-CH-N), 4.32 (1H, d, \( J = 11.5 \) Hz, N-CH-N), 3.98 (2H, q, \( J = 7.1 \) Hz, CH₂-O), 3.90 (2H, d, \( J = 12.7 \) Hz, CH₂-N), 3.71 (2H, d, \( J = 12.7 \) Hz, CH₂-N), 2.18 (3H, s, CH₃-CO), 1.11 (3H, s, CH₃); \(^1^C\) NMR (CDCl₃) \( \delta_{\text{C}} \): 202.0 (C, CO), 168.0 (C, COO), 147.8 (C, Cₐromat), 129.1 (CH, Cₐromat), 125.8 (C, Cₐromat), 119.0 (CH, Cₐromat), 67.4 (CH₂, N-CH₂-N), 61.9 (CH₂, CH₂-CO), 59.9 (C, CH₂-C-CH₂), 53.5 (CH₂, CH₂-N), 26.5 (CH₃, CH₃-CO), 13.8 (CH₃). Anal. calcd. for C₂₁H₂₂Cl₂N₂O₃: C, 59.87; H, 5.26; N, 6.65. Found: C, 60.03; H, 5.28; N, 6.68.

**ACKNOWLEDGMENTS**

The authors thank Fatmeh Soubani, Adnan Abu-Surrah, Bader Salameh, and Kayed Abu-Safieh at the Hashemite University.

**SUPPLEMENTAL MATERIAL**

Supplemental data for this article can be accessed on the publisher’s website.

**REFERENCES**

1. Suzuki, T.; Kubota, T.; Kobayashi, J. Eudistomidins H-K, New \( \beta \)-carboline alkaloids from the Okinawan marine tunicate *Eudistoma glaucus*. *Bioorg. Med. Chem. Lett.* 2011, 21, 4220–4223.
2. Guggisberg, A.; Drandarov, K.; Hesse, M. Protoveroline, the parent member of a class of macrocyclic spermine alkaloids. *Helv. Chim. Acta* 2000, 83, 3035–3042.
3. Drandarov, K.; Guggisberg, A.; Hesse, M. Macrocyclic spermine alkaloids from *Verbascum*: The \((E)/Z\)-isomeric pairs \((-\text{-})\text{-}(S)-verbasitrine/\text{-}(\text{-})\text{-}(S)-isoverbasitrine and \((\text{-})\text{-}(S)-isoverbasitrine/(\text{-})\text{-}(S)- verbametrine: Isolation, structure elucidation, and synthesis. *Helv. Chim. Acta* 1999, 82, 229–234.
4. Renson, B.; Merlin, P.; Daloze, D.; Braekman, J.; Roisin, Y.; Pasteels, J. Biosynthesis of tetraponerine-8, a defence alkaloid of the ant *Tetraponera* sp. *Can. J. Chem.* 1994, 72, 105–109.
5. Braekman, J.; Daloze, D.; Flammang, R.; Maquestiau, A. The fragmentation behaviour of naturally occurring perhydroazepine derivatives. *Org. Mass Spectrom.* 1989, 24, 837–838.
6. Russowski, D.; Canto, R.; Sanches, S.; D’Oca, M.; Fatima, A.; Carvalho, J. Synthesis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: Monastrol, oxo-monastrol, and oxygenated analogues. *Bioorg. Chem.* 2006, 34, 173–182.
7. Bisceglia, J.; Garcia, M.; Massa, R.; Magri, M.; Zani, M.; Gutkind, G.; Orelli, L. Synthesis, characterization, and biological activity of bis(3-aryl-1-hexahydropyrimidinyl)-methanes: Novel heterocyclic polyamine derivatives. *J. Heterocycl. Chem.* 2004, 41, 85–90.
8. Tu, S.; Miao, C.; Fang, F.; Youjian, F.; Li, T.; Zhuang, Q.; Zhang, X.; Zhu, S.; Shi, D. New potential calcium channel modulators: Design and synthesis of compounds containing two pyridine, pyrimidine, pyridone, quinoline, and acridine units under microwave irradiation. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1533–1536.

9. Kappe, C. Biologically active dihydropyrimidones of the Biginelli type: A literature survey. *Eur. J. Med. Chem.* **2000**, *35*, 1043–1052.

10. Siddiqui, A.; Merson-Davies, L.; Cullis, P. The synthesis of novel polyamine-nitroimidazole conjugates designed to probe the structural specificities of the polyamine uptake system in A549 lung carcinoma cells. *J. Chem. Soc., Perkin Trans. 1.* **1999**, *3243–3252*.

11. Kappe, C. One hundred years of the Biginelli dihydropyrimidine synthesis. *Tetrahedron* **1993**, *49*, 6937–6963.

12. Vanelle, P.; Maldonado, J.; Crozet, M.; Senouki, K.; Delmas, F.; Gasquet, M.; Timon-David, P. Préparation et évaluation antiparasitaire de nouveaux imidazoles portant le motif dioxane ou hexahydropyrimidine. *Eur. J. Med. Chem.* **1991**, *26*, 709–714.

13. Bergeron, R.; Seligsohn, H. Hexahydropyrimidines as masked spermidine vectors in drug delivery. *Bioorg. Chem.* **1986**, *14*, 345–355.

14. Golding, B.; Nassereddin, I. The biosynthesis of spermidine, part 2: Preparation and study by $^1$H N.M.R. spectroscopy of hexahydropyrimidines from spermidine and propane-1,3-diamines. *J. Chem. Soc., Perkin Trans. 1.* **1985**, *1*, 2011–2015.

15. Billman, J.; Khan, M. Hexahydropyrimidines, VIII: Synthesis of 2-substituted 1,3-bis[4(N,N-bis[2-chloroethyl]amino)benzyl]hexahydropyrimidines as transport molecules for tumor inhibition. *J. Med. Chem.* **1968**, *11*, 312–314.

16. Smith, P.; Loeppky, R. Nitrosative cleavage of tertiary amines. *J. Am. Chem. Soc.* **1967**, *89*, 1147–1157.

17. de Carvalho, G.; Dias, R.; Pavan, F.; Leite, C.; Silva, V.; Diniz, C.; de Paula, D.; Coimbra, E.; Retailleau, P.; da Silva, A. Synthesis, cytotoxicity, antibacterial, and antileishmanial activities of imidazolidine and hexahydropyrimidine derivatives. *Med. Chem.* **2013**, *9*(3), 351–359.

18. Agbaje, O.; Fadeyi, O.; Fadeyi, S.; Myles, L.; Okoro, C. Synthesis and in vitro cytotoxicity evaluation of some fluorinated hexahydropyrimidine derivatives. *Bioorg. Med. Chem. Lett.* **2011**, *21*(3), 989–992.

19. Martirosyan, A.; Petrosyan, S.; Gasparian, S.; Alexanyan, M.; Panosyan, H.; Martirosyan, V.; Schinazi, R. Synthesis of 6-imino-5-tetrahydro-1H-2-pyrrolylidenehexahydro-2,4-pyrimidinediones as intermediates for the synthesis of C-azanucleosides. *Tetrahedron Lett.* **2010**, *51*(2), 231–233.

20. Enders, D.; Wortmann, L. Asymmetric synthesis of 4,6-disubstituted 1,2,3,4,5,6-hexahydro-5-hydroxypyririmid-2-ones as potential HIV protease inhibitors. *Heterocycles* **2002**, *58*, 293–299.

21. Khan, M.; Gupta, M. Synthesis, anti-inflammatory, and analgesic activity of new hexahydropyrimidine derivatives. *Pharmazie* **2002**, *57*(6), 377–383.

22. Kowalczyk-Bronisz, S. Pharmacological activity of 3-(5-barbiturylo)-propanesulfonic acids derivatives. *Archivum immunologiae et therapiae experimentalis* **1984**, *32*(3), 295–305.

23. Billman, J.; Khan, M. Hexahydropyrimidines, VII: A study of 2-substituted 1,3-bis(2-hydroxy-3-methoxybenzyl)hexahydropyrimidines and 2-substituted 1,3-bis(3,4-dimethoxybenzyl)hexahydropyrimidines as antitumor agents. *J. Med. Chem.* **1966**, *9*(13), 347–351.

24. Billman, J.; Khan, S. Hexahydropyrimidines, V: A study of 2-substituted 1,3-bis(2-cyanobenzyl)hexahydropyrimidines and 2-substituted 1,3-bis(2-chloroethyl)aminoaryl-1,3-bis(aralkyl)hexahydropyrhnidines as antitumor agents. *J. Med. Chem.* **1965**, *8*(4), 498–499.

25. Billman, J.; Meisenheimer, J. Hexahydropyrimidines, IV: Synthesis of 2-[4-[N,N-bis(2chloroethyl)amino]aryl]-1,3-bis(aralkyl)hexahydropyrhnidines as antitumor agents. *J. Med. Chem.* **1964**, *7*(1), 115–117.
26. Tamazyan, R.; Ayvazyan, A.; Martirosyan, V.; Avagyan, K.; Martirosyan, A. 1-Benzyl-6-phenylimino-5-(pyrrol-2-ylidene)hexahydropyrimidine-2,4-dione. Acta Crystallogr., E 2008, 64(2), 483.
27. Azaryan, L.; Avetisyan, S.; Buyukyan, N.; Chachoyan, A.; Garibdzhanyan, B. Synthesis and antitumor activity of 6-(p-alkoxyphenyl) derivatives of hexahydropyrimidine-2,4-diones. Khimiko-Farmatevitchenskii Zh. 1997, 31(6), 8–10.
28. Hwang, J.; Kim, H.; Jo, S.; Park, E.; Choi, J.; Kong, S.; Park, D.; Heo, J.; Lee, J.; Ko, Y.; Choi, I.; Cechetto, J.; Kim, J.; Lee, J.; No, Z.; Windisch, M. Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors. Eur. J. Med. Chem. 2013, 70, 315–325.
29. Jagodzinski, S.; Westerlich, S. Facile and efficient synthesis of 4'-thioxo-1',3',3',4',6'-hexahydro-1H,2'H-spiro[naphthalene-2,5'-pyrimidin]-1-ones in a three-component Mannich-type reaction. Arkivoc 2013, 3, 294–303.
30. Li, J.; Sun, J.; Su, W. Diphenylammonium triflate: A novel and efficient catalyst for synthesis of spiro-heterocyclic compounds. Lett. Org. Chem. 2010, 7(4), 314–318.
31. Gupta, P.; Gupta, S.; Sachar, A.; Kour, D.; Singh, J.; Sharma, L. One-pot synthesis of spiro pyrimidinethiones/spiro pyrimidinones, quinazolinethiones/quinazolinones, and pyrimidopyrimidines. J. Heterocycl. Chem. 2010, 47(2), 324–333.
32. Bose, S.; Idrees, M. An efficient and high-yielding protocol for the synthesis of substituted dihydropyrimidin-2(1h)-ones and spiro-fused heterocycles by involving tandem reactions. Heterocycles 2007, 44(1), 211–214.
33. Zhu, Y.; Pan, Y.; Huang, S. Chemoselective multicomponent condensation of 1,3-cyclohexanedione, urea, or thiourea with aldehydes: One-pot synthesis of two families of fused heterobicyclic and spiro-fused heterobicyclic aliphatic rings. Heterocycles 2005, 65(1), 133–142.
34. Abelman, M.; Smith, C.; James, R. Cyclic ketones and substituted α-keto acids as alternative substrates for novel Biginelli-like scaffold syntheses. Tetrahedron Lett. 2003, 44(24), 4559–4562.
35. Mukhopadhyay, C.; Rana, S.; Butcher, J. FeCl₃-catalysed two consecutive aminomethylation at the α-position of the β-dicarbonyl compounds: An easy access to hexahydropyrimidines and its spiro analogues. Tetrahedron Lett. 2011, 52(32), 4153–4157.
36. Sivasubramanian, M.; Subbu, P.; Abdulrahman, I. Facile catalyst-free pseudo five-component domino reactions in the expedient synthesis of 5-aryloyl-1,3-diarylhexahydropyrimidines. Tetrahedron Lett. 2012, 53, 1144–1148.
37. Kimura, T.; Minabe, M.; Tsubota, M.; Suzuki, K. Decacylations and syntheses of some 9-acylfluorenes. Bull. Chem. Soc. Jpn. 1977, 51(1), 258–260.
38. Neudeck, H. Aromatische Spirane, 14: Mitt. Darstellung von 2,2'-Spirobi-(s-hydrindacen) und seinen Vorstufen. Monatsh. Chem. 1987, 118(5), 627–657.
39. Bennur, T.; Joshi, N. Alkali cleavage of α,α disubstituted β-ketoesters, nitriles, and β-diketones. Indian J. Chem., Sect. B 2003, 42B(3), 670–671.